To determine whether calcium channel blockers influence the progression of coronary atherosclerosis, 383 patients age 65 years or less with 5-75% stenoses in at least four coronary artery segments were selected at random within 1 Ninety-two nicardipine patients (55%) and 95 placebo patients (57%) had progression at one or more sites (p=NS). Regression, that is, an improvement by l1o0 or more in diameter stenosis, was seen in 140 of 2,323 lesions (6.0%) overall, with no significant intergroup difference. Among the 217 patients with 411 stenoses of 20% or less in the first study, such minimal lesions progressed in only 15 of 99 nicardipine patients compared with 32 of 118 placebo patients (15% versus 27%, p =0.046). In this subgroup, 16 of 178 minimal lesions in nicardipine patients and 38 of 233 minimal lesions in placebo patients progressed (p=0.038). By stepwise logisticregression analysis, baseline systolic blood pressure (p=0.04) and the change in systolic blood pressure between baseline and 6 months (p=0.002) correlated with progression of minimal lesions. This suggested blood pressure reduction may account for the beneficial action of nicardipine. These results suggested nicardipine has no effect on advanced coronary atherosclerosis but may retard the progression of minimal lesions. (Circulation 1990;82:1940-1953 Several calcium channel blockers have been shown to retard the development of athero-1, sclerosis in rabbits fed cholesterol-rich diets.1-7 The mechanism through which these drugs exert their antiatherogenic effects is not known, but is being From the
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with factors"l previously shown to be associated with a high incidence of disease progression. Methods 
Patient Selection
The design features of this trial, including the criteria for patient selection, were described in detail in a previous report.'2 The use of coronary angiographic end points instead of clinical end points (such as mortality plus nonfatal myocardial infarction) and the selection of patients at higher risk for coronary disease progression substantially reduce 35 .2±-mmmm20.6
Previous myocardial infarction (n) 85 (44) Previous heart failure (n) 6 (3.1) Stable angina (n) 122 (64) Duration (mo) 32 .2±mmm39. 1 Atypical chest pain 48 (25) Angina class (n) (17) 70 (37) 86 (45) 3 (1.6) 6.74±+1.31
1.06+0.30
110 (57) 6 (3.1) 30 (16) 4 (2.1) 35 (18) 7 (3.6) 21 (11) 54 (28) 73 (38) 44 (23) 62.1 +9.6 sample size requirements. In a retrospective analysis"1 of 313 medically treated patients who had two coronary arteriograms at the Montreal Heart Institute, the only two variables available at the first arteriogram that independently predicted progression were younger age and higher extent score. Extent score was obtained by dividing the coronary tree into the 15 segments defined in the Coronary Artery Surgery Study. 13 The score was calculated by counting the number of coronary segments containing stenoses of 5-75% of the lumen diameter.11 '12 Thus, a patient with a 40% stenosis in each of the three major coronary arteries and with no other lesions would have an extent score of 3 but "zero vessel disease" according to the standard clinical classification. In our retrospective data base,1' patients meeting the age and extent score criteria listed in Table 1 had an 80% probability of coronary disease progression in 2-4 years. Thus, these criteria Placebo (n = 191) 50 .0+8.4 157 (82) 61 (32) 3 (1.6) 135 (71) 46 (24) (26) 32 (17) 90 (47) 60 (31) 9 (4.7) 6.98 +1.47 1.05+0.26 114 (60) 10 (5.2) 29 (15) 4 (2.1) 28 (15) 14 (7.3) 35 (18) 54 (28) 73 (38) 29 (15) 30 .6±38. 6 97 (25) 65 (17) 160 (42) 146 (38) (16) 21 (5.5) 56 (15) 108 (28) 146 (38) 73 (19) 
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Circulation Vol 82, No 6, December 1990 were used to select patients for the present study. However, the expected progression rate in this study was not necessarily 80% because the interval between angiograms was only 2 years, patients were restudied prospectively regardless of symptoms, and progression was assessed by quantitative instead of visual methodology.
All patients undergoing coronary arteriography at the Montreal Heart Institute were screened for entry into the trial. Patients were tracked until they were either enrolled in the study or declared ineligible.
Men, or women without childbearing potential, age 21-65 years were selected. Other eligibility criteria were 1) coronary arteriography performed within 1 month of study entry; 2) presence of the age and extent score criteria listed in Table 1 ; 3) written permission for the study from the patient's cardiologist, who concurred with the decision plan for medical therapy during the study period; 4) written informed consent from the patient; and 5) stable medical therapy for at least 3 weeks preceding study entry.
Exclusion criteria were 1) previous coronary bypass surgery or coronary angioplasty; 2) planned coronary bypass surgery or coronary angioplasty, or patients for whom the treating physician wished to retain these therapeutic options in the months after coronary arteriography; 3) clinically significant valvular heart disease, 4) ejection fraction of less than 40%, 5) left ventricular aneurysm possibly requiring surgery, 6) any coexisting severe illness that would make repeat arteriography ethically unjustifiable, 7) severe advanced coronary disease judged to be inoperable, 8) left main coronary artery stenosis of more than 50%, 9) three-vessel disease (Coronary Artery Surgery Study criteria)13 plus preseptal left anterior descending coronary artery stenosis of more than 70%, 10) participation in other therapeutic intervention trials, 11) variant angina or other conditions for which treatment with a calcium channel blocker is mandatory, 12) severe uncontrolled hypertension (supine diastolic pressure of more than 120 mm Hg) despite antihypertensive treatment, or systemic hypotension (systolic pressure of less than 90 mm Hg), 13) unstable angina at the time of study entry, 14) second-or third-degree atrioventricular block or any uncontrolled cardiac arrhythmia other than sinus arrhythmia or occasional extrasystoles, 15) myocardial infarction within 1 month before study entry, 16) any condition likely to hinder or confuse follow-up evaluation, 17) clinically important, abnormal pretreatment renal or hepatic blood tests, 18) abnormal tri-iodothyronine or thyroxine levels, if untreated, 19) a coronary event or other medical catastrophe after the screening angiogram but before study entry, 20) a technically suboptimal or incomplete screening coronary arteriogram, and 21) patient living too far from the institute to return for follow-up visits. The trial was approved by our hospital ethics committee.
From the 8,915 coronary arteriograms done between July 1984 and December 1986 at our institute, 449 patients (5%) were identified who met the age and extent score inclusion criteria and who had none of the exclusion criteria; 383 (85%) were selected at random for the study. Patients were enrolled and began study medication within 1 month of their coronary arteriogram. The characteristics of the study patients are listed in Table 2 .
Study Protocol
Patients were selected at random in a double-blind fashion to receive nicardipine capsules, 30 mg three times daily, or a matching placebo. This was done by assigning consecutive numbers to patients at the time of selection. Study medication was then dispensed at each visit by the hospital pharmacy according to the patient's number. The pharmacist (and no one else) had access to a list of patient numbers followed by a code letter (A or B) designating the treatment as either nicardipine or placebo. If mild side effects developed, the dose could be reduced to 20 mg three times daily while maintaining double-blinding.
Patients were seen after enrollment at weeks 1, 2, and 4, and at months 2, 3, 6, 9, 12, 15, 18, 21, and 24. With the exception of other calcium channel blockers, concomitant medications were allowed; antianginal medication was encouraged to limit the number of dropouts to bypass surgery or coronary angioplasty. Indeed, only one placebo patient and two nicardipine patients crossed over to a calcium channel blocker, and only one patient (in the placebo group) was lost to coronary bypass surgery. The details of data collection at each visit and data management have been described. 12 Compliance to use of study medication was monitored by a capsule count at each visit and by measurements of plasma nicardipine levels 1-3 hours postdose. Compliance averaged greater than 90% at each visit by capsule count. All patients had blood drawn for plasma nicardipine levels at months 1, 6, and every 6 months thereafter. Two randomly selected samples from each of 50 randomly chosen patients receiving active treatment were assayed for plasma nicardipine levels. In only one of the 100 samples was the drug concentration below the quantification limit of the assay (1 ng/ml). The mean plasma concentration was 54.5+36.9 ng/ml. In 10 randomly selected samples from placebo patients, the plasma nicardipine level was always less than the quantification limit of the assay.
All cardiovascular intercurrent events were categorized according to predetermined standard definitions12 by one investigator without knowledge of treatment assignment. Intercurrent events, adverse effects, concomitant medication profiles, compliance data, and new electrocardiographic or laboratory abnormalities were evaluated according to treatment assignment by an independent monitoring committee that met at 6-month intervals.
Interpretation of Coronary Arteriograms
Repeat coronary arteriography was planned at 24 months after enrollment but was performed earlier on 37 patients. The interval from study entry to repeat arteriography was 13.6±6.9 months in the 21 nicardipine patients and 13.3 ± 6.9 months in the 16 placebo patients who had early repeat arteriography. The reason for early arteriography was myocardial infarction in 12 patients, unstable or worsening angina in 21 patients, and a persistent, unacceptable level of stable angina in four patients. One week before repeat coronary arteriography, study medication was routinely discontinued and antianginal medication was adjusted to be identical to that taken at the time of the first arteriogram. In less than 5% of the study patients, the first arteriogram was obtained during an intravenous infusion of nitroglycerin due to unstable angina; in these cases, intravenous nitroglycerin was also infused the second time. Otherwise, nitroglycerin was not routinely used. When coronary spasm was suspected during arteriography, the involved vessel was refilmed after nitroglycerin administration. Care was taken to avoid vessel overlap and to ensure matching camera angulation between the studies.
Each pair of arteriograms was interpreted together by one of three experienced cardiovascular radiologists blinded with respect to the order of films, treatment assignment, and patient identity. For each lesion, an end-diastolic frame from each arteriogram with identical angulation that best showed the stenosis was selected by the radiologist. When the severity of the lesion appeared to differ in different views, the clearest view showing the stenosis at its most severe was chosen.
The Cardiovascular Angiographic Analysis System (CAAS) developed by Reiber et al1415 was used to measure coronary lesions quantitatively in this study, as previously described in detail.12 An experienced technician, blinded to the patient's identity, treatment assignment, and the order of the films, used this system to measure the coronary stenosis from the frame selected by the radiologist. The cineframe was digitized and displayed on a video monitor. The image was calibrated based on the known size of the cardiac catheter, and a correction was made for pin-cushion distortion. The region of interest was magnified; after the technician selected preliminary centerline points in the arterial segment under analysis, an automatic edge detection program determined the arterial borders by assessing brightness along scan lines perpendicular to the centerline. A software smoothing procedure was then applied to the contours and arterial diameter in millimeters was displayed for the length of the segment analyzed. The normal diameter of the arterial segment was determined either at a user-indicated reference position or as a computer-estimated interpolated diameter. Percent diameter stenosis was calculated using the interpolated diameter as the denominator, except in rare situations such as lesions in branching segments, in which reference diameter was more accurate.
The reproducibility of repeated measurements from the same frame14,16 or from another end-diastolic frame17 was excellent and superior to the reproducibility of visual assessments.18 Because the pair of films for each patient was read simultaneously with the order blinded, segments with slight or no visible irregularities were measured on one film if the other showed a stenosis at that site. As a result, only 15 of 2,323 lesions (0.6%) were counted as 0% stenoses at the first arteriogram and could have been classified as new lesions.
Measurements of two orthogonal views of each lesion were not done. In a previous study16 using CAAS, we found that measurements of the view showing the stenosis at its most severe were sufficient. Lesions in arteries of 1 mm diameter or smaller were read visually because the system is less reliable under these circumstances. As shown by Brown et al,19 computer-assisted measurements exhibited low variability over a wide range of stenosis severity; visual estimates were most variable for stenoses of intermediate severity. Stenoses of 25% or less appear at arteriography as only minimal irregularities of the arterial wall and can be accurately assessed visually, which is in contrast to lesions of more than 25%. Among 355 lesions of less than 30% assessed visually and measured quantitatively, the mean difference between the two techniques for percent stenosis was 1.5% and the SD was 8.3%. This degree of variability is only slightly higher than the 5.6% SD of repeat quantitative measurements from arteriograms done within 1 month in our laboratory. Therefore, in the present study, a stenosis of 25% or less on both films was interpreted visually but not by quantitative arteriography when the radiologist judged that no change had occurred. All but 4% (19 of 457) of the lesions with progression or regression were measured quantitatively; among stenoses of 20% or less with progression, 91% (49 of 54) were measured quantitatively.
No consensus exists as to the best criterion for defining progression or regression from serial coronary arteriograms. Variability of measurement is less for absolute stenosis diameter than for percent diameter stenosis.20 When progressive coronary disease narrows both the stenosis and the adjacent "normal" segment, this worsening is detected by measurement of the absolute stenosis diameter. Yet the percent diameter stenosis, which is the ratio of absolute stenosis diameter to "normal" segment diameter, may not change. Clearly, more than one isolated measurement is required to accurately define progression or regression. Three criteria were prospectively selected in this study-a minimum diameter change of 0.4 mm or more, a percent diameter stenosis change of 10% or more, and, using videodensitometry, a percent area stenosis change of 10% or more. ' Table 2 , the random selection process achieved a balanced distribution. The major coronary events that occurred during the study are listed according to treatment assignment in Table 3 . Two nicardipine patients and three placebo patients died; four of the five deaths were sudden, and all were presumed to be due to coronary disease. Myocardial infarction was diagnosed when predetermined, standard criteria were fulfilled.12 Fourteen nicardipine patients had 17 definite myocardial infarctions, and eight placebo patients experienced nine definite infarctions (p=0.27). Fourteen nicardipine patients and 14 placebo patients required hospitalization for worsening angina. One of the placebo patients was hospitalized twice for separate episodes. The differences between groups for coronary events are not statistically significant.
Of the 383 patients enrolled in the trial, a second coronary arteriogram suitable for analysis was obtained in 335 (87%). In addition to the five patients who died, 22 nicardipine patients and 21 placebo patients either dropped out of the trial or refused the second arteriogram at 24 months. With the exception of one nicardipine patient who developed unstable angina, a second coronary arteriogram was obtained in all patients with myocardial infarction or worsening angina during the trial. Among the 335 patients who had a second arteriogram, only one patient (in the nicardipine group) had crossed over to a calcium channel blocker during the trial; only four nicardipine patients and five placebo patients had discontinued study medication.
Hemodynamic and Metabolic Changes
Arterial blood pressure, heart rate, total cholesterol, and high density lipoprotein (HDL) cholesterol were measured regularly during the trial because the levels could influence coronary disease progression. Arterial pressure decreased significantly after the baseline visit in both groups (p<0.01) -from 132+19/83+10 to 120+16/76±10 mmHg at the Defining progression as an increase in stenosis diameter of 10% or more increased the proportion of patients with progression from 43 to 56%; however, the rates in the nicardipine and placebo groups remained similar-92 of 168 (55%) versus 95 of 167 (57%), respectively. Similarly, regression of at least one lesion was found in 53 nicardipine patients (32%) and 50 placebo patients (30%), using the definition of an improvement in percent stenosis diameter of 10% or more. None of the differences between the groups for progression or regression using either criteria approaches statistical significance. A typical coronary stenosis with regression is illustrated in Figure 1 .
Overall, 2,323 lesions were evaluated in 335 patients as shown in seen in 6.4% of nicardipine lesions and in 5.6% of placebo lesions (p=0.43).
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Progression of Coronary Stenoses of 20% or Less
To test the hypothesis that early lesions might be amenable to drug therapy, the 217 patients with lesions of 20% or less on the first of their two arteriograms were examined separately. Ninety-nine of the 217 patients were in the nicardipine group, and 118 patients were in the placebo group. With respect to the baseline clinical and angiographic characteristics listed in Table 6 , the two groups were well (31) 16 (16) 39 (39) 42 (42) 2 (2) 6.88± (20) 3 (3) 19 (19) 3 (3) 15 (15) 31 (31) 36 (36) 17 (17) (31) 24 (20) 55 (47) 35 (30) 4 (3) 7.01 ± (14) 3 (3) 12 (10) 6 (5) 27 (23) 35 (30) 45 (38) 11 (9) (31) 40 (18) 94 (43) 77 (36) 6 (3) 6.95± (14) 9 (4) 42 (19) 60 (30) 81 (37) 28 (13) balanced. The placebo patients were slightly younger-49.6+8.0 versus 51.5+7.7 years (p =0.08) -and had a shorter duration of angina -27.6+33.1 versus 38.3±44.6 months (p=0.13). Previous myocardial infarction had occurred in 41 of 99 nicardipine patients and in 61 of 118 placebo patients (41% versus 52%,p=0. 14). During the trial, total and HDL cholesterol levels were similar in the two groups (p always >0.10); arterial blood pressure was slightly lower in nicardipine patients, as it was for the entire study population. Concomitant medication profiles were also similar to those of the entire study.
Coronary stenoses .50% were present in a similar distribution in the two treatment groups, as listed in Table 6 . Slightly more minimal lesions were present in the placebo group: 54 nicardipine patients and 50 placebo patients had one minimal lesion, 19 nicardipine patients and 37 placebo patients had two such lesions, and 26 nicardipine patients and 31 placebo patients had three or more (p=0.09). Overall, 178 stenoses of 20% or less were present in the 99 nicardipine patients and 233 in the 118 placebo patients (1.80 versus 1.97 stenoses per patient, respectively).
As shown in Table 7 , progression of minimal lesions was more common in placebo patients than in nicardipine patients. Using the criterion of a minimum diameter decrease of 0.4 mm or more, 12 of 99 nicardipine patients and 28 of 118 placebo patients had progression of at least one stenosis of 20% or less (12% versus 24%, p=0.035); 7.3% (13 of 178) of nicardipine lesions and 14.2% (33 of 233) of placebo lesions progressed (p=0.039). Using the criterion of a percent stenosis increase of 10% or more, 15 nicardipine patients (15%) and 32 placebo patients (27%) had progression (p=0.046); 9.0% of stenoses of 20% or less in nicardipine-treated patients and 16.3% of such lesions in placebo-treated patients progressed (p=0.038).
A typical coronary stenosis of 20% or less that progressed is illustrated in Figure 2 . Among lesions of 20% or less that progressed, the mean increase was from 15.2±6.9% to 40.4±12.6% stenosis in the nicardipine group and from 14.3±5.5% to 44 .6±20.6% in the placebo group. Among the 54 lesions of 20% or less with progression, 15 (28%) progressed to a 50% or more stenosis -five in the nicardipine group and 10 in the placebo group.
Factors Related to Progression of Stenoses of 20% or Less
Stepwise logistic-regression analysis was used to examine the effect of nicardipine on progression of stenoses of 20% or less by adjusting for covariates. For the 217 patients with these lesions, 31 baseline clinical and angiographic variables and blood pressure change between the baseline and 6-month follow-up visit were included. For the analyses listed in Table 8 , progression was defined as an increase in stenosis severity by 10% or more.
Model 1 includes the treatment factor and a constant. It shows that nicardipine minimal lesions have a 31% lesser chance of progressing than do placebo minimal lesions [1-exp(83) x 100%]. Baseline systolic blood pressure and change in systolic blood pressure between baseline and 6 months were selected by the stepwise procedure and are included in Model 2. After adjusting for these covariates, the effect of nicardipine is no longer significant (p=0.188). Because nicardipine lowers blood pressure, it may be more appropriate to exclude blood pressure changes from the final model. Therefore, Model 3 includes all covariates except blood pressure changes. Under these conditions, aspirin usage had a significant inhibitory effect on progression of minimal lesions. The beneficial effect of nicardipine remained statistically significant with aspirin included in the model. of hemodynamically important coronary lesions would be preferable to a drug without this feature.
Clinical End Points
The numbers of patients who died, suffered myocardial infarction, or developed worsening angina requiring hospitalization are small, and differences among treatment groups do not attain statistical significance. However, myocardial infarction occurred in 14 nicardipine patients compared with eight placebo patients, a trend that may be meaningful. In two studies of nifedipine in survivors of myocardial infarction, a significantly higher mortality was seen in treated patients than in those receiving a placebo.24.25 Because of its short duration and small sample size, our trial would be unlikely to detect any influence of nicardipine on major cardiovascular end points.
Advantageous Features of Trial Design
Due to the restrictive inclusion criteria, the mean number of coronary stenoses per patient was 6.9, yet most patients had no more than mild symptoms. Thus, the angiographic follow-up rate was very high -87% of all randomly selected patients -and the incidence of progression on a per-patient basis was high enough to ensure that a significant beneficial effect of the drug on progression would be detected.
The angiographic end point of disease progression is more sensitive than clinical end points but is equally relevant because progression will eventually produce worsening angina, myocardial infarction, or death. Progression can now be assessed reliably with quantitative techniques, as was done in the present study. The results of this trial with respect to minimal lesions should be interpreted cautiously. The criterion used to define this category, a stenosis of 20% or less, is arbitrary and unlikely to correlate closely with any morphologic or pathophysiologic feature of atherosclerosis. This part of the analysis was done retrospectively and involved fewer patients and lesions than the primary analyses. By chance, more minimal lesions and more patients with these lesions were in the placebo group. Nevertheless, on either a per-patient or a per-lesion basis, the rate of progression of minimal lesions was markedly lower in the nicardipine group.
Other Studies
The International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT), a European multicenter, randomly selected and placebo-controlled trial32 to assess the effect of nifedipine on the progression of coronary disease, has recently been completed. Nifedipine did not influence the progression of established stenoses but significantly reduced the number of new lesions developing during treatment. 33 The investigators defined a new lesion as a stenosis of more than 20% at the second arteriogram that was either not present or less than 20% at the first study. This definition corresponds roughly to the minimal lesions that progressed in our study.
The magnitude of the beneficial nifedipine effect on new lesions in INTACT and of nicardipine on the progression of minimal lesions in our study are remarkably similar. In addition, a smaller, non-randomly selected study reported less progression over 3 years in nifedipine-treated patients compared with those taking propranolol or isosorbide dinitrate. 34 
Mechanism ofAction
Animal experiments suggest several mechanisms that could account for the beneficial effect of calcium channel blockers on minimal lesions.8,9 Endothelial injury may accelerate the early development of atheroscleroSiS35; the calcium channel blocker isradipine preserves endothelial function in cholesterol-fed rabbits,5 and nicardipine blocks the potassium-induced increase in permeability across the endothelium of the isolated rabbit aorta.36 Intracellular lipid accumulation is an important component of the atherosclerotic plaque. In the aorta of the cholesterol-fed rabbit, both nifedipine37 and verapamil38 block cholesteryl ester accumulation. Intimal smooth-muscle cell proliferation, a response to intimal injury, can be limited by isradipine39 and nifedipine40; nicardipine inhibits smooth muscle cell migration. 41 In this trial, baseline systolic blood pressure and the change in systolic blood pressure between baseline and the 6-month follow-up visit were the two factors that correlated best with progression of minimal lesions by multivariate analysis: Progression was associated with higher baseline systolic pressures that decreased less during treatment. This finding suggests that the mechanism of action through which nicardipine exerts its beneficial effect may be blood pressure reduction. In large clinical studies, treating hypertension reduced the incidence of stroke much more than the incidence of coronary end points.42 It has been suggested that an adverse effect of diuretic treatment in susceptible hypertensives might have negated the benefit of blood pressure reduction. 43 Newer antihypertensive drugs might therefore exert a more favorable influence on coronary end points.
In 370 low-risk coronary patients selected at random to receive a placebo or active treatment for 5 years, Chesebro et al found that aspirin reduced not only the incidence of new infarcts but also the number of new coronary lesions, according to a preliminary report.44 In our trial, both aspirin and nicardipine were associated with less progression of minimal lesions by multivariate analysis.
Implications
To date, most attempts to modify the course of coronary atherosclerosis in humans have involved cholesterol reduction, by either diet or drugs. [45] [46] [47] The possibility that calcium channel blockers might act synergistically with cholesterol lowering to induce regression and retard progression should be considered, particularly for early lesions. For advanced lesions where the risk of thrombosis is higher, antiplatelet drugs such as aspirin probably play a greater role. Aspirin may also reduce the formation of new lesions. Nicardipine had no effect on advanced lesions in this study, nor did nifedipine in the INTACT study.33 It is therefore unlikely that different results would be found with other dihydropyridine calcium channel blockers.
